Justin Cidado

2.9k total citations
36 papers, 561 citations indexed

About

Justin Cidado is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Justin Cidado has authored 36 papers receiving a total of 561 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Molecular Biology, 12 papers in Oncology and 9 papers in Hematology. Recurrent topics in Justin Cidado's work include Cancer-related Molecular Pathways (10 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Cell death mechanisms and regulation (7 papers). Justin Cidado is often cited by papers focused on Cancer-related Molecular Pathways (10 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Cell death mechanisms and regulation (7 papers). Justin Cidado collaborates with scholars based in United States, United Kingdom and Brazil. Justin Cidado's co-authors include Ben Ho Park, Lisa Drew, Rory L. Cochran, Wenjing Tao, Daniel J. Zabransky, Marc O. Warmoes, Bing Z. Carter, Philip L. Lorenzi, Hong Yuen Wong and Vivian Ruvolo and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Justin Cidado

36 papers receiving 559 citations

Peers

Justin Cidado

ONCOL

HEMAT

PRM

Isha Kapoor India

Milena Vuica‐Ross United States

Bei Jin China

Sylvanie Surget France

Nicole E. McNeil United States

Marjan Geugien Netherlands

Florian Bellutti Austria

Keyi Zhu United States

Tanyifor M. Tohnya United States

Alexander Hoellein Germany

Isha Kapoor India

Justin Cidado

376 ×1.0

141 ×0.8

ONCOL

84 ×0.9

HEMAT

81 ×1.0

35 ×0.5

PRM

Citations per year, relative to Justin Cidado Justin Cidado (= 1×) peers Isha Kapoor

Countries citing papers authored by Justin Cidado

Since Specialization

Citations

This map shows the geographic impact of Justin Cidado's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Justin Cidado with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Justin Cidado more than expected).

Fields of papers citing papers by Justin Cidado

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Justin Cidado. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Justin Cidado. The network helps show where Justin Cidado may publish in the future.

Co-authorship network of co-authors of Justin Cidado

This figure shows the co-authorship network connecting the top 25 collaborators of Justin Cidado. A scholar is included among the top collaborators of Justin Cidado based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Justin Cidado. Justin Cidado is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kannan, Sankaranarayanan, Yizhen Li, Natalia Baran, et al.. (2024). Antileukemia efficacy of the dual BCL2/BCL-XL inhibitor AZD0466 in acute lymphoblastic leukemia preclinical models. Blood Advances. 9(3). 473–487. 5 indexed citations

Wen, Shenghua, Graeme Scarfe, Justin Cidado, et al.. (2023). A PKPD Case Study: Achieving Clinically Relevant Exposures of AZD5991 in Oncology Mouse Models. The AAPS Journal. 25(4). 66–66. 1 indexed citations

Arulananda, Surein, Megan A. O’Brien, Marco Evangelista, et al.. (2021). A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma. Cell Death Discovery. 7(1). 122–122. 30 indexed citations

Carter, Bing Z., Po Yee Mak, Wenjing Tao, et al.. (2020). Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and re-sensitizes acute myeloid leukemia to BCL-2 inhibition. Haematologica. 107(1). 58–76. 82 indexed citations

Li, Yijing, Yang Liu, Courtney L. Andersen, et al.. (2020). AZD4320 Is a Novel and Potent BCL-2/XL Dual Inhibitor in Targeting Aggressive Mantle Cell Lymphoma. Blood. 136(Supplement 1). 44–44. 2 indexed citations

Danilova, Olga V., Erin Gilbert, Craig Okada, et al.. (2019). Cyclin-Dependent Kinase-9 Is a Therapeutic Target in MYC-Expressing Diffuse Large B-Cell Lymphoma. Molecular Cancer Therapeutics. 18(9). 1520–1532. 40 indexed citations

Montero, Joan, Cécile Gstalder, Daniel J. Kim, et al.. (2019). Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies. Nature Communications. 10(1). 5157–5157. 42 indexed citations

Boiko, Scott, Theresa A. Proia, Maryann San Martin, et al.. (2019). Abstract 2500: Transient CDK9 inhibition with AZD4573 modulates Bfl-1 in preclinical lymphoma models. Cancer Research. 79(13_Supplement). 2500–2500. 1 indexed citations

Koch, Raphael, Amanda L. Christie, Jennifer L. Crombie, et al.. (2018). Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas. Blood. 133(6). 566–575. 35 indexed citations

10.

Cidado, Justin, J. Paul Secrist, Francis D. Gibbons, et al.. (2018). Abstract 311: AZD4320 is a potent, dual Bcl-2/xLinhibitor that rapidly induces apoptosis in preclinical hematologic tumor models. Cancer Research. 78(13_Supplement). 311–311. 5 indexed citations

11.

Boiko, Scott, Theresa A. Proia, Maryann San Martin, et al.. (2018). Abstract 306: A mechanistic rationale for combining acalabrutinib with CDK9 inhibitor, AZD4573, in ABC-DLBCL. Cancer Research. 78(13_Supplement). 306–306. 4 indexed citations

12.

Matulis, Shannon M., Vikas A. Gupta, Jonathan J. Keats, et al.. (2018). Preclinical Activity of Novel MCL1 Inhibitor AZD5991 in Multiple Myeloma. Blood. 132(Supplement 1). 952–952. 5 indexed citations

13.

Cidado, Justin, Theresa A. Proia, Scott Boiko, et al.. (2018). Abstract 310: AZD4573, a novel CDK9 inhibitor, rapidly induces cell death in hematological tumor models through depletion of Mcl1. Cancer Research. 78(13_Supplement). 310–310. 10 indexed citations

14.

Croessmann, Sarah, Hong Yuen Wong, Daniel J. Zabransky, et al.. (2017). PIK3CA mutations and TP53 alterations cooperate to increase cancerous phenotypes and tumor heterogeneity. Breast Cancer Research and Treatment. 162(3). 451–464. 17 indexed citations

15.

Cidado, Justin, Minhui Shen, Michael Grondine, et al.. (2016). Abstract 3572: AZ5576, a novel potent and selective CDK9 inhibitor, induces rapid cell death and achieves efficacy in multiple preclinical hematological models. Cancer Research. 76(14_Supplement). 3572–3572. 3 indexed citations

16.

Cochran, Rory L., Justin Cidado, Daniel J. Zabransky, et al.. (2015). Functional isogenic modeling of BRCA1 alleles reveals distinct carrier phenotypes. Oncotarget. 6(28). 25240–25251. 9 indexed citations

17.

Cochran, Rory L., Karen Cravero, David Chu, et al.. (2014). Analysis of BRCA2 loss of heterozygosity in tumor tissue using droplet digital polymerase chain reaction. Human Pathology. 45(7). 1546–1550. 10 indexed citations

18.

Cidado, Justin & Ben Ho Park. (2012). Targeting the PI3K/Akt/mTOR Pathway for Breast Cancer Therapy. Journal of Mammary Gland Biology and Neoplasia. 17(3-4). 205–216. 84 indexed citations

19.

Higgins, Michaela J., Julia A. Beaver, Hong Yuen Wong, et al.. (2011). PIK3CAmutations and EGFR overexpression predict for lithium sensitivity in human breast epithelial cells. Cancer Biology & Therapy. 11(3). 358–367. 7 indexed citations

20.

Liang, Yurong, Kenneth B. Christopher, Justin Cidado, et al.. (2003). Analysis of cytokine functions in graft rejection by gene expression profiles1. Transplantation. 76(12). 1749–1758. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact